{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["14(13)"],"submitter":["Liu JY"],"pubmed_abstract":["We report a galactosyl diiodo-BODIPY-based nanoparticles as type-I photosensitizer (PS) with high water solubility for HepG2 cell targeted photodynamic therapy. Functionalized galactoside and glucoside were introduced into diiodo-BODIPY to obtain BP1 and BP2, respectively. The glycolyl PSs could self-assemble to form the nanoparticles BP1-NP and BP2-NP with red-shifted near-infrared (NIR) absorption and fluorescence at 682 nm and 780 nm, as well as excellent chemo- and photo-stability. In comparison to the monomer in DMSO, the aggregated photosensitizers in the nanoparticles enabled the sensitization of oxygen to superoxide (O<sub>2</sub>˙<sup>-</sup>) through a type-I process, while repressing the generation of singlet oxygen (<sup>1</sup>O<sub>2</sub>) through a type-II process. The galactosyl-modified BP1-NPs could target and concentrate on HepG2 cells, subsequently generating O<sub>2</sub>˙<sup>-</sup> and <sup>1</sup>O<sub>2</sub> to trigger cell death under 660 nm light irradiation. This work provides an efficient strategy for the construction of glycoside-recognized type-I photosensitizers for tumor cell imaging and photodynamic therapy."],"journal":["RSC advances"],"pagination":["8735-8739"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10938552"],"repository":["biostudies-literature"],"pubmed_title":["Galactosyl BODIPY-based nanoparticles as a type-I photosensitizer for HepG2 cell targeted photodynamic therapy."],"pmcid":["PMC10938552"],"pubmed_authors":["Tian Y","Dong L","Liu JY"],"additional_accession":[]},"is_claimable":false,"name":"Galactosyl BODIPY-based nanoparticles as a type-I photosensitizer for HepG2 cell targeted photodynamic therapy.","description":"We report a galactosyl diiodo-BODIPY-based nanoparticles as type-I photosensitizer (PS) with high water solubility for HepG2 cell targeted photodynamic therapy. Functionalized galactoside and glucoside were introduced into diiodo-BODIPY to obtain BP1 and BP2, respectively. The glycolyl PSs could self-assemble to form the nanoparticles BP1-NP and BP2-NP with red-shifted near-infrared (NIR) absorption and fluorescence at 682 nm and 780 nm, as well as excellent chemo- and photo-stability. In comparison to the monomer in DMSO, the aggregated photosensitizers in the nanoparticles enabled the sensitization of oxygen to superoxide (O<sub>2</sub>˙<sup>-</sup>) through a type-I process, while repressing the generation of singlet oxygen (<sup>1</sup>O<sub>2</sub>) through a type-II process. The galactosyl-modified BP1-NPs could target and concentrate on HepG2 cells, subsequently generating O<sub>2</sub>˙<sup>-</sup> and <sup>1</sup>O<sub>2</sub> to trigger cell death under 660 nm light irradiation. This work provides an efficient strategy for the construction of glycoside-recognized type-I photosensitizers for tumor cell imaging and photodynamic therapy.","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Mar","modification":"2025-04-22T12:56:23.662Z","creation":"2025-04-06T00:29:23.722Z"},"accession":"S-EPMC10938552","cross_references":{"pubmed":["38495974"],"doi":["10.1039/d4ra00041b"]}}